What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity?

Vikki M. Abrahams, Maria O. Borghi, Pier Luigi Meroni, Jacob H. Rand, Elen A. Raschi, Jane E. Salmon, Francesco Tedesco, Angel A. Tincani

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Pregnancy complications are a frequent and unsolved condition in patients with antiphospholipid syndrome (APS). Women with antiphospholipid antibodies (aPL) are at high risk of recurrent early pregnancy loss, as well as late obstetrical complications associated with impaired placental function, such as preeclampsia, intrauterine growth restriction, and prematurity. Thrombotic events at the maternal–fetal interface were originally thought to underlie aPL-associated pregnancy complications, due to the partial beneficial effects of heparin. However, more recent clinical and experimental observations suggest, instead, that non-thrombotic events may play a primary role in the pathophysiology of pregnancy complications in APS patients, including complement activation, inflammation, and disruption of normal trophoblast function. This chapter will review the known pathogenic mechanisms of pregnancy complications in APS and provide a helpful instrument to all the workers in the field from both a clinical and basic view.

Original languageEnglish
Title of host publicationAntiphospholipid Syndrome
Subtitle of host publicationInsights and Highlights from the 13Th International Congress on Antiphospholipid Antibodies
PublisherSpringer US
Number of pages23
ISBN (Electronic)9781461431947
ISBN (Print)9781461431930
StatePublished - 1 Jan 2012
Externally publishedYes


Dive into the research topics of 'What is the mechanism(S) of antiphospholipid antibody-mediated pregnancy morbidity?'. Together they form a unique fingerprint.

Cite this